Literature DB >> 10085005

Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.

C A Lobo1, R Dhar, N Kumar.   

Abstract

Immunological intervention, in addition to vector control and malaria chemotherapy, will be needed to stop the resurgence of malaria, a disease with a devastating impact on the health of 300 to 500 million people annually. We have pursued a vaccination strategy, based on DNA immunization in mice with genes encoding two antigens present on the sexual stages of Plasmodium falciparum, Pfs25 and Pfg27, to induce biologically important antibodies that can block development of the parasite in the Anopheles mosquito and thus transmission of the disease. DNA encoding Pfs25 when administered by the intramuscular route, either alone or with DNA encoding Pfg27, had the most potent transmission-blocking effects, resulting in up to a 97% decrease in oocyst numbers in mosquito midguts and a 75% decrease in rate of infection. Immunization with DNA encoding a Pfg27-Pfs25 fusion protein was less effective and DNA encoding Pfg27 elicited antibodies in sera that had only modest effects on the infectivity of the parasite. These results show for the first time that DNA vaccination can result in potent transmission-blocking antibodies in mice and suggest that the Pfs25 gene should be included as part of a multicomponent DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085005      PMCID: PMC96515          DOI: 10.1128/IAI.67.4.1688-1693.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  Sexual differentiation in malaria parasites.

Authors:  P Alano; R Carter
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

2.  Plasmodium gallinaceum: exflagellation stimulated by a mosquito factor.

Authors:  M M Nijhout
Journal:  Exp Parasitol       Date:  1979-08       Impact factor: 2.011

3.  The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.

Authors:  I A Quakyi; R Carter; J Rener; N Kumar; M F Good; L H Miller
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

Review 4.  Immunity to sexual stages of malaria parasites.

Authors:  R Carter; N Kumar; I Quakyi; M Good; K Mendis; P Graves; L Miller
Journal:  Prog Allergy       Date:  1988

5.  Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures.

Authors:  A N Vermeulen; J van Deursen; R H Brakenhoff; T H Lensen; T Ponnudurai; J H Meuwissen
Journal:  Mol Biochem Parasitol       Date:  1986-08       Impact factor: 1.759

6.  Antibody avidity determination by ELISA using thiocyanate elution.

Authors:  G R Pullen; M G Fitzgerald; C S Hosking
Journal:  J Immunol Methods       Date:  1986-01-22       Impact factor: 2.303

7.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

8.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

9.  Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites.

Authors:  Y Charoenvit; S Mellouk; C Cole; R Bechara; M F Leef; M Sedegah; L F Yuan; F A Robey; R L Beaudoin; S L Hoffman
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

10.  Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito.

Authors:  A N Vermeulen; T Ponnudurai; P J Beckers; J P Verhave; M A Smits; J H Meuwissen
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

View more
  25 in total

1.  Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.

Authors:  Ralph LeBlanc; Yessika Vasquez; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

2.  Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice.

Authors:  Gregory S Noland; Debabani Roy Chowdhury; Joseph F Urban; Fidel Zavala; Nirbhay Kumar
Journal:  Vaccine       Date:  2010-02-25       Impact factor: 3.641

Review 3.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 4.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

5.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

6.  Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.

Authors:  Dibyadyuti Datta; Geetha P Bansal; Brooke Grasperge; Dale S Martin; Mario Philipp; Dietlind Gerloff; Barry Ellefsen; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2017-11-10       Impact factor: 3.641

7.  Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Authors:  Rajesh Kumar; Paresh C Ray; Dibyadyuti Datta; Geetha P Bansal; Evelina Angov; Nirbhay Kumar
Journal:  Vaccine       Date:  2015-08-20       Impact factor: 3.641

Review 8.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

9.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.

Authors:  Cevayir Coban; Mario T Philipp; Jeanette E Purcell; David B Keister; Mobolaji Okulate; Dale S Martin; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.